Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo ® (nivolumab)

This material is intended to notify the press release issued on March 20 (local time) by Bristol Myers Squibb, our license partner for Opdivo. Please click https://www.bms.com/media/press-releases.html for the original press release.

The release as fetched from its publisher. ono-pharma.com ↗